Targeted therapies in the Oncology field and of the related different needs
Traditional statistical design of clinical trials in Oncology (phases of studies, standard endpoints...)
Requirements of the regulatory authorities, with a special focus on the rebounds in the European and Italian System (with examples of major criticisms of some relevant trials)
Analysis of the new endpoints related to the different mechanism of action of the new therapies will be provided
Phase III statistical design of clinical trials in Oncology, in particular with new drugs (analysis of recent examples of phase III trials which present limitations)
Meaning of the terms deviation, violation and exception and their impact on the clinical trials conduction and results
Who should Attend
Professionals involved in the design of clinical trials in Oncology
Companies involved in the development of new anti-cancer drugs
Monitors
Production Managers
Investors
CROs
Medical Oncologists
Past Events
How to design and to interpret a clinical trial in the targeted therapies Era 2015 - 19-20 Feb 2015, Courtyard Boston Logan Airport, Massachusetts, United States (47326)
How to design and to interpret a clinical trial in the targeted therapies Era 2015 - 22-23 Jan 2015, Hilton Grand Vacations Suites at the Flamingo, Las Vegas, Nevada, United States (47347)
How to design and to interpret a clinical trial in the targeted therapies Era 2026
Important
Please, check "How to design and to interpret a clinical trial in the targeted therapies Era" official website for possible changes, before making any traveling arrangements
Event Categories
Health & Medicine: Hospitals & Clinics, Medical laboratories
